Yüklüyor......
Brentuximab Vedotin in CD30+ Lymphomas
Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin’s lymphoma (cHL) and anaplastic la...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer Healthcare
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3873074/ https://ncbi.nlm.nih.gov/pubmed/24392301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13554-013-0008-7 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|